

November 22, 2007

Astellas Announces Acquisition of Treasury Shares

(Acquisition of Treasury Shares pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Japan, November 22, 2007 – Astellas Pharma Inc. (“the Company”, headquarters: Tokyo, President and CEO: Masafumi Nogimori) announced that at the meeting of the Board of Directors held today, a resolution was adopted acquisition of Treasury Shares pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act:

Particulars

1. Reasons for the acquisition of Treasury Shares
In order to improve capital efficiency and enhance return to shareholders
 2. Contents of acquisition
 - (1) Class of shares subject to be acquired: Common stock of the Company
 - (2) Total number of shares to be possibly acquired:
8 million shares (Maximum)
(The percentage compared to the total number of issued shares (excluding Treasury Shares):1.58%)
 - (3) Aggregate amount of acquisition cost: 40 billion yen (Maximum)
 - (4) Period of acquisition: From December 3, 2007 to January 18, 2008
- (Reference) The status of Treasury Shares as of October 31, 2007
- | | |
|--|--------------------|
| Total number of issued shares (excluding Treasury Shares): | 506,071,772 shares |
| Number of Treasury Shares: | 12,892,863 shares |

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com